Skip to content

Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization

Prospective Study on the Role of Intravenous Unfractionated Heparin Following Digital Replantation and Revascularization

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04725201
Enrollment
188
Registered
2021-01-26
Start date
2021-05-24
Completion date
2027-05-01
Last updated
2026-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amputation; Traumatic, Hand

Keywords

Replantation, Revascularization, Unfractionated heparin, Finger

Brief summary

The purpose of this study is to determine the effectiveness of therapeutic dose intravenous heparin at improving replantation/revascularization success and its indications (if any) in participants who have suffered traumatic digital amputation. Digital replantation/revascularization success will be assessed in participants who receive continuous intravenous drip of thromboprophylactic heparin at a therapeutic dose (i.e. modifies INR to the desired range) contrasted to those who do not receive therapeutic dose heparin (i.e. does not modify INR to the desired range). In the study, replantation/revascularization success is defined as a clearly viable digit at the time of discharge. Secondary objectives include assessing postoperative complications associated with heparin use, such as bleeding, hematoma or heparin induced thrombocytopenia. The investigators would also assess the impact of categorical variables such as smoking status, mechanism of injury and comorbidities, on digital survival.

Interventions

DRUGIntravenous unfractionated heparin

See experimental arm description for intervention description.

DRUGSham

See sham comparator arm description for intervention description.

Sponsors

Centre hospitalier de l'Université de Montréal (CHUM)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Prospective randomized double-blinded clinical trial

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All replantation and revascularization patients who are accepted into the CEVARMU program at the Centre hospitalier de l'Université de Montréal

Exclusion criteria

* Patients on anticoagulants, other than ASA, prior to admission (i.e. Coumadin, Eliquis, Pradaxa, Plavix, or similar medications) * Patients with a contraindication for heparin (e.g. coagulopathy, acute ulcers, thrombocytopenia, severe liver damage, shock) * Patients who suffered an amputation in the level of the carpal tunnel and proximal to it * Patients who experienced a degloving injury

Design outcomes

Primary

MeasureTime frameDescription
Success of digit replantation or revascularizationUp to 14 daysSuccess is defined as a clearly viable digit, determined by saturation with a pulse oximeter or by bleeding on needle pinprick.

Secondary

MeasureTime frameDescription
Heparin-related complicationsUp to 14 daysComplications include but are not limited to bleeding at or away from site of injury, hematoma, heparin-induced thrombocytopenia.

Countries

Canada

Contacts

CONTACTLinda M Zhu
linda.zhu@mail.mcgill.ca5148908000
PRINCIPAL_INVESTIGATORBruno Mastropasqua, MD FRCSC

Université de Montréal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026